BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward ...
Shares of Matinas Biopharma Holdings, Inc. (NYSE:MTNB – Get Free Report) fell 6.6% during mid-day trading on Tuesday .The company traded as low as $0.53 and last traded at $0.56. 46,870 shares ...
Matinas BioPharma (NYSE:MTNB) Holdings, Inc. (NYSE American:MTNB), a pharmaceutical company specializing in the development ...
BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase ...
Evelyn D’An has been appointed as an independent director and Chair of the Audit Committee, bringing extensive corporate governance and financial oversight experience to Matinas BioPharma's ...
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery ...
Short interest in Matinas BioPharma Holdings Inc (AMEX:MTNB) increased during the last reporting period, rising from 297.62K to 348.23K. This put 7.02% of the company's publicly available shares ...
Matinas BioPharma Holdings, Inc. BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry ...
Thank you for your patience and understanding. About Matinas BioPharmaMatinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback